ÖZET
Amaç:
Bu çalışmada kliniğimize başvuran Sjögren sendromu (SS) tanılı hastalarımızın demografik, klinik ve serolojik özelliklerin değerlendirmesi amaçlandı.
Gereç ve Yöntem:
Çalışmaya Ocak 2015 ve Nisan 2019 tarihleri arasında polikliniğimize başvuran SS tanılı 49 hasta dahil edildi. Hastaların geriye dönük olarak yaş, cinsiyet, SS’nin primer/sekonder olma durumu; sekonder ise hangi hastalığa eşlik ettiği, ilişkili olabilecek diğer kronik hastalıkların varlığı, tükürük bezi biyopsisi ve otoantikor değerlendirme sonuçları kaydedildi.
Bulgular:
Çalışmaya katılan 49 hastanın (46 kadın, 3 erkek) yaş ortalaması 48,39±11,45 yıl (minimum: 18, maksimum: 81) idi. Kadın/erkek oranı 15,3/1 idi. Hastaların 34’ü (%69,4) primer SS tanısı alırken, 15’i (%30,6) sekonder SS idi. En yaygın başvuru yakınması kuru göz (%98) ve kuru ağız (%92) idi. Çalışmamızda anti-nükleer antikorlar pozitifliği %40,8 olarak saptanırken, romatoid faktör pozitifliği %28,6 idi. Hastaların %46,9’unda Anti-SS-A; %26,5’inde ise anti-SS-B pozitifti.
Sonuç:
SS’de klinik bulgular, serolojik belirteçler ve semptomlar heterojendir. Hastaların semptom şiddeti ve çeşitliliği diğer eşlik eden romatizmal hastalıklardan da etkilenir.
References
1
Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.
2
Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 2010;9:A305-10.
3
Dafni UG, Tzioufas AG, Staikos P, Skopouli FN, Moutsopoulos HM. Prevalence of Sjögren’s syndrome in a closed rural community. Ann Rheum Dis 1997;56:521-5.
4
Nocturne G. [Sjögren’s syndrome update: Clinical and therapeutic aspects]. Rev Med Interne 2019;40:433-9.
5
Johnsen SJ, Brun JG, Goransson LG, Smastuen MC, Johannesen TB, Haldorsen K, et al. Risk of non-Hodgkin’s lymphoma in primary Sjogren’s syndrome: a population-based study. Arthritis Care Res (Hoboken) 2013;65:816-21.
6
Nocturne G, Pontarini E, Bombardieri M, Mariette X. Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford) 2019;kez052. [Epub ahead of print] doi: 10.1093/rheumatology/kez052
7
Kamalı S, Kasapoğlu E, Çefle A, Sayarlıoğlu M, Öcal L, Gül A, et al. Primer Sjögren Sendromlu 35 Hastanın Klinik ve Laboratuar Özellikleri: İstanbul Tıp Fakültesi Romatoloji Bilim Dalı Tecrübesi. İst Tıp Fak Mecmuası 2004;67:2:104-8.
8
Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87.
9
Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:1983-9.
10
Sandhya P, Jeyaseelan L, Scofield RH, Danda D. Clinical Characteristics and Outcome of Primary Sjogren’s Syndrome: A Large Asian Indian Cohort. Open Rheumatol J 2015;9:36-45.
11
Alani H, Henty JR, Thompson NL, Jury E, Ciurtin C. Systematic review and meta-analysis of the epidemiology of polyautoimmunity in Sjögren’s syndrome (secondary Sjögren’s syndrome) focusing on autoimmune rheumatic diseases. Scand J Rheumatol 2018;47:141-54.
12
Dörtbaş F, Garip Y, Güler T, Karci AA. Coexistence of Familial Mediterranean Fever With Ankylosing Spondylitis and Sjogren’s Syndrome: A Rare Occurrence. Arch Rheumatol 2015;31:87-90.
13
Tanaka M, Migita K, Miyashita T, Maeda Y, Nakamura M, Komori A, et al. Coexistence of familial Mediterranean fever and Sjögren’s syndrome in a Japanese patient. Clin Exp Rheumatol 2007;25:792.
14
Romos-Casals M, Pilar BZ, Raphaèle S, Hendrika B, Simon J B, Thomas D, et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford) 2017;56:1245.
15
Vassiliou VA, Moyssakis I, Boki KA, Moutsopoulos HM. Is the heart affected in primary Sjögren’s syndrome? An echocardiographic study. Clin Exp Rheumatol 2008;26:109-12.
16
Evans R, Zdebik A, Ciurtin C, Walsh SB. Renal involvement in primary Sjögren’s syndrome. Rheumatology (Oxford) 2015;54:1541-8.
17
Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008;87:210-9.
18
Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanovas A, Sopeña B, et al. Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014;53:321-31.
19
Corominas H, Ortiz-Santamaría V, Castellví I, Moreno M, Morlà R, Clavaguera T, et al. Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies. Rheumatol Int 2016;36:365-9.
20
García-Carrasco M, Sisó A, Ramos-Casals M, Rosas J, de la Red G, Gil V, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002;29:726-30.
21
Lafitte C, Amoura Z, Cacoub P, Pradat-Diehl P, Picq C, Salachas F, et al. Neurological complications of primary Sjögren’s syndrome. J Neurol 2001;248:577-84.
22
Barendregt PJ, van den Bent MJ, van Raaij-van den Aarssen VJ, van den Meiracker AH, Vecht CJ, van der Heijde GL, et al.Involvement of the peripheral nervous system in primary Sjögren’s syndrome. Ann Rheum Dis 2001;60:876-81.
23
Moreira I, Teixeira F, Martins Silva A, Vasconcelos C, Farinha F, Santos E. Frequent involvement of central nervous system in primary Sjögren syndrome. Rheumatol Int 2015;35:289-94.
24
Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren’s Syndrome. Rheum Dis Clin North Am 2016;42:419-34.
25
Shen L, Suresh L. Autoantibodies, detection methods and panels for diagnosis of Sjögren’s syndrome. Clin Immunol 2017;182:24-9.
